Skyhawk Therapeutics, Inc. has expanded its collaboration with Biogen, extending Biogen's exclusive license to worldwide rights beyond the original research-stage therapeutic candidates for the treatment of conditions including multiple sclerosis (MS), spinal muscular atrophy (SMA) and additional neurological disorders, leveraging Skyhawk's SkySTAR technology platform.
Skyhawk receives an upfront payment from Biogen and may receive potential future milestone payments and royalties.
"Biogen is a leading neuro-focused biopharmaceutical company with a compelling history of drug development across a range of challenging conditions," said Bill Haney, co-founder and chief executive officer of Skyhawk. "Their strong scientific culture has already produced a series of leading global therapeutics and our work together to date has gone very well. We are excited to expand our opportunity to work together to help more patients with challenging unmet medical needs."
Breaking News
Skyhawk, Biogen Expand Alliance in Neurological Disorders
Skyhawk receives an upfront payment and is eligible for future milestones and royalties
07.08.19
Related Content
-
Collaborations & Alliances | Drug Discovery
Confo Therapeutics, DyNAbind to Collaborate on Drug Discovery
Aims to identify novel small molecule GPCR-modulating compounds07.03.19
-
Collaborations & Alliances | Drug Development
Voyager Therapeutics, Sanofi Genzyme Restructure Gene Therapy Alliance
Voyager gains worldwide rights to VY-HTT01 Huntington’s disease program and ex-U.S. rights to VY-FXN01 Friedreich’s ataxia program for $10 million upfront06.17.19
-
Trials & Filings
AveXis’ Zolgensma Aproved for Pediatric Patients with Spinal Muscular Atrophy
The first and only gene therapy approved by the FDA for the treatment of SMA, including those who are pre-symptomatic at diagnosis06.13.19
-
Biologics, Proteins, Vaccines | Drug Development
The Future Is… Therapeutic
As cell and gene therapies rise, so too does outsourcingBen Locwin 06.13.19
-
Drug Development | Industry News
Biogen Completes $800M Nightstar Acquisition
Gains two mid- to late-stage clinical assets and preclinical programs in ophthalmology06.07.19
